RxDoctor Payments Data

Maryann Mays, MD

Neurology · Cleveland, OHNPI 1043274681

Payments from drug & device makers

$187,887in general payments, 2019–2025

Across 302 payments — averaging $622.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$110K
  • Amgen$35K
  • Teva Pharmaceuticals USA, Inc.$28K
  • Eli Lilly$4K
  • Lundbeck LLC$3K
  • Biodelivery Sciences International, Inc.$3K
  • plus $5K from 11 others

What the payments were for

  • Consulting fees$25,42215%
  • Speaking & faculty fees$129,76175%
  • Travel & lodging$7,7744%
  • Food & beverage$10,2696%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$187,887 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$32,220
Medicare patients
180
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate36$63,733
Emgality PenGalcanezumab-Gnlm44$41,970
Ajovy AutoinjectorFremanezumab-Vfrm45$38,064
QuliptaAtogepant21$31,487
Aimovig AutoinjectorErenumab-Aooe23$26,042
UbrelvyUbrogepant13$19,056
Ajovy SyringeFremanezumab-Vfrm12$8,349
Desvenlafaxine Succinate ErDesvenlafaxine Succinate19$2,245
Eletriptan HbrEletriptan Hydrobromide15$1,526
Gabapentin63$1,225
Sumatriptan Succinate18$1,192
Naratriptan Hcl27$833
Duloxetine Hcl27$583
Topiramate37$555
Baclofen12$554

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$2,265$63,73336 claims
AbbVieQulipta, Ubrelvy$110,100$50,54334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →